Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazarotene Cream 0.05% vs TAZORAC® in Plaque Psoriasis
NCT02886702Phase 3Completed
- Sponsor
- Fougera Pharmaceuticals Inc.
- Start
- Sep 2016
- Primary completion
- Aug 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tazarotene in plaque psoriasis (3 arms), sponsored by Fougera Pharmaceuticals Inc. Primary endpoint: Treatment Success Assessed by Investigator's Global Assessment at 12 weeks. Started Sep 2016; status: completed.
02
Drugs
tazarotene
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02886702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02886702.